Corcept Therapeutics Inc

Corcept Therapeutics insider buying signals confidence amid litigation; investors gain insight into market strategy, competitive positioning, and drug‑development prospects.

CEO sells 26,000 Corcept shares under a 10b‑5 plan after FDA Lifyorli approval, reflecting disciplined liquidity management rather than market speculation.

Corcept insider buying signals confidence in its GR‑II obesity therapy, as CEO William Guyer’s 2026 trades hint at future upside amid a competitive market and clinical progress.

Corcept Therapeutics insider trades reveal portfolio rebalancing, not distress, amid rising social‑media buzz—watch leadership moves for future growth signals.

James Wilson’s $0.00 sale of 28,000 Corcept shares shows insider tactical rebalancing amid a 15% month‑to‑date dip; investors should watch for future moves that could signal company milestones.

Insider buying by Corcept Therapeutics’ owner signals confidence despite FDA and legal headwinds, offering investors a stabilizing signal amid market volatility.

Corcept Therapeutics insiders buy 1.18 M options, boosting confidence amid a 41% share decline and pending fraud lawsuit.

Corcept insider trades reveal strategic confidence amid earnings miss – James Wilson buys at $3.88, sells at $36.48, signalling liquidity strategy and voting power consolidation for future option exercises and long‑term growth.